Drug research

Vatiquinone

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as EPI-743; PTC743

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaNCT05485987	PTC Therapeutics	Phase 2	Completed	2024-08-29Actual
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaNCT04577352	PTC Therapeutics	Phase 2, Phase 3	Completed	2023-04-04Actual
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich AtaxiaNCT05515536	PTC Therapeutics	Phase 3	Active not recruiting	2027-12-31Estimated
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseaseNCT05218655	PTC Therapeutics	Phase 3	Completed	2025-04-15Actual
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyNCT04378075	PTC Therapeutics	Phase 2, Phase 3	Terminated	2023-03-18Actual

PTC TherapeuticsCompletedPrimary completion: 2024-08-29 · Actual

Trial details

PTC TherapeuticsCompletedPrimary completion: 2023-04-04 · Actual

Trial details

PTC TherapeuticsActive not recruitingPrimary completion: 2027-12-31 · Estimated

Trial details

PTC TherapeuticsCompletedPrimary completion: 2025-04-15 · Actual

Trial details

PTC TherapeuticsTerminatedPrimary completion: 2023-03-18 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.